# A novel germline CDH23 variant as a likely cause of an ultra-giant prolactinoma

**Authors:** Eman Albasri, Balgees Alghamdi, Avaniyapuram Kannan Murugan, Eyas Othman, Sarah Alotaibi, Mohammad Anas Dababo, Ahmed Alfares, Ali S. Alzahrani

PMC · DOI: 10.1186/s13023-025-04161-w · Orphanet Journal of Rare Diseases · 2026-01-29

## TL;DR

A woman with an ultra-giant prolactinoma was found to have a new CDH23 gene variant, which may be a cause of this rare tumor type.

## Contribution

A novel germline CDH23 variant is identified as a likely cause of an ultra-giant prolactinoma.

## Key findings

- The patient had a prolactin level of 277,500 ng/ml, indicating an ultra-giant prolactinoma.
- Whole exome sequencing revealed a novel CDH23 variant (c.2621C > A, p.Ala874Asp) in the patient.
- Treatment with cabergoline led to significant symptom improvement and tumor response.

## Abstract

Giant prolactinomas are defined as pituitary adenomas (PAs) ≥ 4 cm with plasma prolactin level > 1000 ng/ml with no other co-secretory component. The reasons for development of giant prolactinomas are not clear but genetics play an important pathogenic mechanism in some PAs. In this report, we describe a middle-aged woman who incidentally was found to have an infiltrative giant prolactinoma involving the sellar, supra- and parasellar regions and occupying most of the middle fossae of the skull extending all the way to the occipital and upper cervical regions. Anteriorly, it extends to the sphenoid and parasellar sinuses, nasopharynx and nasal cavities. It was initially thought to be a nasopharyngeal cancer but biopsy from a protruding component from the right nostril showed that it was a prolactinoma. Prolactin level after several dilutions was extremely high at 277,500 ng/ml (normal range 3.4–24.1 ng/ml). Surprisingly, her pituitary function evaluation showed only mild central hypothyroidism [(FT4 11.4 pmol/l (normal range 12–22) and TSH 1.9 mU/l (normal range 0.27–4.2)] and hypogonadotropic hypogonadism (E2 47 pmol/l, LH 1.9 u/l, FSH 5.9 u/l). Cosyntropin stimulation test was normal suggesting normal pituitary adrenal axis but insulin-induced hypoglycaemia test was not performed. In retrospect, the patient reported chronic nasal congestion and snoring, headaches on/off and deterioration in her hearing and visual acuity over the last few years. She ascribed these symptoms to sinusitis and advancing age, respectively. Whole exome sequencing revealed a novel variant in CDH23 (NM_022124.6:c.2621C > A, p.Ala874Asp), a gene that has been previously reported to be associated with PAs. The patient was treated with small doses of cabergoline (0.5 mg twice weekly) and reported remarkable improvement in her symptoms. Radiological evaluation confirmed the significant response of this giant prolactinoma to cabergoline.

## Linked entities

- **Genes:** CDH23 (cadherin related 23) [NCBI Gene 64072]
- **Chemicals:** cabergoline (PubChem CID 54746)
- **Diseases:** hypothyroidism (MONDO:0005420), hypogonadotropic hypogonadism (MONDO:0018555), prolactinoma (MONDO:0010911)

## Full-text entities

- **Genes:** PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, GNAS (GNAS complex locus) [NCBI Gene 2778] {aka AHO, AIMAH1, C20orf45, GNAS1, GPSA, GSA}, USP8 (ubiquitin specific peptidase 8) [NCBI Gene 9101] {aka HumORF8, PITA4, SPG59, UBPY}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, AIP (AHR interacting HSP90 co-chaperone) [NCBI Gene 9049] {aka ARA9, FKBP16, FKBP37, PITA1, SMTPHN, XAP-2}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, SF3B1 (splicing factor 3b subunit 1) [NCBI Gene 23451] {aka Hsh155, MDS, PRP10, PRPF10, SAP155, SF3b155}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, TTF1 (transcription termination factor 1) [NCBI Gene 7270] {aka TTF-1, TTF-I}, PCDH15 (protocadherin related 15) [NCBI Gene 65217] {aka CDHR15, DFNB23, USH1F}, MEN1 (menin 1) [NCBI Gene 4221] {aka MEAI, SCG2}, ATRX (ATRX chromatin remodeler) [NCBI Gene 546] {aka JMS, MRX52, RAD54, RAD54L, XH2, XNP}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, CDH23 (cadherin related 23) [NCBI Gene 64072] {aka CDHR23, PITA5, USH1D}, KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085] {aka AAD10, ALR, BCAHH, CAGL114, KABUK1, KMS}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, DAXX (death domain associated protein) [NCBI Gene 1616] {aka BING2, DAP6, EAP1}, CDKN1B (cyclin dependent kinase inhibitor 1B) [NCBI Gene 1027] {aka CDKN4, KIP1, MEN1B, MEN4, P27KIP1}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, PRKAR1A (protein kinase cAMP-dependent type I regulatory subunit alpha) [NCBI Gene 5573] {aka ACRDYS1, ADOHR, CAR, CNC, CNC1, PKR1}, USP48 (ubiquitin specific peptidase 48) [NCBI Gene 84196] {aka DFNA85, RAP1GA1, USP31}
- **Diseases:** Cushing syndrome (MESH:D003480), hypoglycemia (MESH:D007003), somatolactotroph adenoma (MESH:D000236), Giant pituitary neuroendocrine tumors (MESH:D018358), amenorrhea (MESH:D000568), quadriparesis (MESH:D011782), herniation (MESH:D004677), visual field defect (MESH:D005128), hearing impairment (MESH:D034381), homonymous hemianopia (MESH:D006423), sensory or motor deficits (MESH:D001289), type 2 diabetes mellitus (MESH:D003924), seizure (MESH:D012640), Usher syndrome (MESH:D052245), dysphagia (MESH:D003680), sinusitis (MESH:D012852), malignancy (MESH:D009369), hirsutism (MESH:D006628), vomiting (MESH:D014839), diplopia (MESH:D004172), diabetic or hypertensive retinopathy (MESH:D058437), hearing and visual impairment (MESH:D006311), panhypopituitarism (MESH:C563172), acne (MESH:D000152), Giant prolactinomas (MESH:D015175), hypertension (MESH:D006973), PA (MESH:C535387), orthostatic hypotension (MESH:D007024), sensorineural deafness (MESH:D006319), PAs (MESH:D010911), acromegaly (MESH:D000172), cranial nerve palsy (MESH:D003389), oligomenorrhea (MESH:D009839), optic atrophy (MESH:D009896), renal impairment (MESH:D007674), tumorigenesis (MESH:D063646), nasal obstruction (MESH:D015508), hyperprolactinemia (MESH:D006966), Central adrenal insufficiency (MESH:D000309), galactorrhea (MESH:D005687), paresthesia (MESH:D010292), facial palsy (MESH:D005158), nasopharyngeal cancer (MESH:D009303), nasal congestion (MESH:D009668), sensory loss (MESH:C580162), snoring (MESH:D012913), retinitis pigmentosa (MESH:D012174), chronic renal insufficiency (MESH:D051436), fever (MESH:D005334), otorrhea (MESH:D002558), gynecomastia (MESH:D006177), cough (MESH:D003371), trauma (MESH:D014947), CSF leak (MESH:D002559), non-syndromic autosomal recessive deafness (OMIM:601072), central hypothyroidism (MESH:D007037), weight loss (MESH:D015431), hypogonadism (MESH:D007006), impaired memory (MESH:D008569), sensorineural and conduction (MESH:D046089)
- **Chemicals:** levothyroxine (MESH:D013974), dopamine (MESH:D004298), E2 (MESH:D004958), FT4 (-), cortisol (MESH:D006854), 18F- Fluorodeoxyglucose (MESH:D019788), glucose (MESH:D005947), calcium (MESH:D002118), gadolinium (MESH:D005682), alanine (MESH:D000409), H&amp;E (MESH:D006371), Cabergoline (MESH:D000077465)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.1096 G > A, Alanine to Aspartic acid, c.906 G > C, p.Ala874Asp, Arg1379Leu, p.Asp302Glu
- **Cell lines:** NM_022124.6 — Bos taurus (Bovine), Finite cell line (CVCL_3074)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12857099/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12857099/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12857099/full.md

---
Source: https://tomesphere.com/paper/PMC12857099